Get 40% Off
🤯 This Tech Portfolio is up 29% YTD! Join Now to Get April’s Top PicksGet The Picks – Just 99 USD

COVID vaccine protection highly likely to wane over time - UK advisers say

Published 30/07/2021, 14:35
Updated 30/07/2021, 17:16
© Reuters. FILE PHOTO: A person receives a dose of the Pfizer BioNTech vaccine, at vaccination centre for young people and students at the Hunter Street Health Centre, amid the coronavirus disease (COVID-19) outbreak, in London, Britain, June 5, 2021. REUTERS/Henry

© Reuters. FILE PHOTO: A person receives a dose of the Pfizer BioNTech vaccine, at vaccination centre for young people and students at the Hunter Street Health Centre, amid the coronavirus disease (COVID-19) outbreak, in London, Britain, June 5, 2021. REUTERS/Henry

LONDON (Reuters) -The protection that vaccines give against coronavirus infection, and potentially severe disease, is highly likely to wane over time so vaccine campaigns will continue for years to come, scientists told the British government's advisory group.

"It is highly likely that vaccine induced immunity to SARS-CoV-2 infection, and potentially severe disease (but probably to a lesser extent) will wane over time," according to an executive summary of a document considered by the government's Scientific Advisory Group for Emergencies (SAGE).

"It is therefore likely that there will be vaccination campaigns against SARS-CoV-2 for many years to come, but currently we do not know what will be the optimal required frequency for re-vaccination to protect the vulnerable from COVID disease," the scientists said.

The document, titled "How long will vaccines continue to protect against COVID?", was written by prominent virologists and epidemiologists from Imperial College London, University of Birmingham and Public Health England.

Britain has approved and is using three shots - Oxford-AstraZeneca, Pfizer-BioNTech and Moderna (NASDAQ:MRNA) - in a mass vaccination programme that started in December 2020.

Real world data show that these vaccines protect with 95% or greater effectiveness against the Alpha variant that dominated in Britain in early 2021, the scientists said, although the ability of the shots to protect against infection and onward transmission was lower.

They said it might be expected that vaccine effectiveness would remain high for severe disease but effectiveness against mild disease and infection could fall off over time.

Anecdotal reports from Britain and Israel, which rolled out a comprehensive early campaign, supported that concept, they said.

Israel will begin offering a third shot of the Pfizer-BioNTech COVID-19 vaccine to people aged over 60, a world first in efforts to slow the spread of the highly contagious Delta variant.

Since the emergence of the Delta variant, the Israeli health ministry has twice reported a drop in the vaccine's efficacy against infection and a slight decrease in its protection against severe disease.

© Reuters. FILE PHOTO: A person receives a dose of the Pfizer BioNTech COVID-19 vaccine at a mass vaccination centre for those aged 18 and over at the London Stadium, amid the coronavirus pandemic, in east London, Britain, June 19, 2021. REUTERS/Henry Nicholls

In a separate report to the UK government on July 22, scientists said there was a "realistic possibility" that new strains could emerge that could lead to more widespread severe disease or evade the impact of the current vaccines.

The emergence of such strains could lead to a return to tighter controls and lockdowns, with a consequent impact on economic activity.

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.